INS and diabetic ketoacidosis: Discrepancies between clinical studies and the real-world results are expected and have been reported as up to 27%.16,17 Clinical studies on insulin therapy usually exclude subjects prone to hypoglycemia or diabetic ketoacidosis (DKA), thus potentially biasing the estimation of adverse events in these trials.